Edge Rewrite
// HTMLRewriter · presentation

This page was redesigned at the edge.

Cloudflare fetched the original article and streamed it through HTMLRewriter to apply an entirely new visual system without rebuilding the source page.

// request.cf · coarse context

A page that knows where it met you.

Only coarse request metadata is shown. This demo does not display or persist visitor IP addresses.

Country
US
Cloudflare location
CMH
Connection
HTTP/2
Language
Not provided

Ray ID: a2a6383e5e7b6c75

Jump to content

Jonathan Leo

From Wikipedia, the free encyclopedia

Jonathan Leo
EducationMacalester College
University of Iowa
Scientific career
FieldsNeuroanatomy
InstitutionsKansas City University
Thesis Alcohol-induced neuropathology in the neonatal rat brain  (1995)
Nicholas Pantazis

Jonathan T. Leo is a former Professor of Anatomy at Lincoln Memorial University in Harrogate, Tennessee and former Associate Professor of Anatomy at the Alabama College of Osteopathic Medicine.[1][2] He is currently the Chair of Pathology and Anatomical Sciences and a Professor of Anatomy at the Kansas City University College of Osteopathic Medicine.[3] He has published articles critical of chemical and biological theories of mental illness. He is the former editor-in-chief of Ethical Human Psychology and Psychiatry. With Sami Timimi, he is also the co-editor of the book Rethinking ADHD.[4][5]

JAMA controversy

[edit]

In 2008, Leo and Jeffrey Lacasse co-authored a letter to the editor that was published in JAMA. The letter criticized a randomized controlled trial that had been published in JAMA aimed at determining the effectiveness of the antidepressant drug escitalopram in the treatment of stroke. Leo and Lacasse criticized the original trial for not directly comparing the effectiveness of escitalopram with that of problem-solving therapy.[6] After this letter was published, Leo discovered through a Google search that one of the authors of the escitalopram paper, psychiatrist Robert Robinson, had received speaking fees from Forest Laboratories, the company that produces and sells the drug under the name Lexapro. Robinson had not disclosed this conflict of interest in the paper. Five months later, Leo and Lacasse published a letter on the website of the BMJ pointing out this conflict of interest.[7]

References

[edit]
  1. "Jonathan Leo, PhD". Lincoln Memorial University. Retrieved July 17, 2019.
  2. "Faculty & Staff".
  3. "Faculty Details". www.kansascity.edu. Retrieved January 29, 2026.
  4. Goldhill, Olivia (December 29, 2017). "30 years after Prozac arrived, we still buy the lie that chemical imbalances cause depression". Quartz. Retrieved July 17, 2019.
  5. "Johnathan Leo, Ph.D. bio". NARPA. Retrieved July 17, 2019.
  6. Lacasse, Jeffrey (October 15, 2008). "Escitalopram, Problem-Solving Therapy, and Poststroke Depression". JAMA. 300 (15): 1757–8, author reply 1758–9. doi:10.1001/jama.300.15.1757-c. ISSN 0098-7484. PMID 18854528.
  7. Leo, Jonathan; Jeffrey Lacasse, Assistant Professor of Social Work (July 11, 2019). "Clinical Trials of Therapy versus Medication: Even in a Tie, Medication wins". BMJ. 338 (feb05 1): b463. doi:10.1136/bmj.b463. ISSN 0959-8138. S2CID 57582276.
[edit]